Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner
作者： Panagiotis J. Vlachostergios , Eleana Hatzidaki , Christina D. Befani , Panagiotis Liakos , Christos N. Papandreou
DOI: 10.1007/S10637-013-9968-1
关键词:
摘要: … factor involved in poor responses and dismal prognosis of this tumor, despite marginal benefits achieved after introduction of concurrent chemoradiation and adjuvant temozolomide (…
core.ac.uk
springer.com
sci-hub.se 
researchgate.net 参考文章(57)
Anthony E. Pegg, Sreenivas Kanugula, Natalia A. Loktionova, O6-Alkylguanine-DNA Alkyltransferase Humana Press. pp. 321- 343 ,(2011) , 10.1007/978-1-61737-995-6_15
Santosh Kesari, Masayuki Nitta, Clark C Chen, Alan D'Andrea, Kimberly Ng, Andrew Kung, Lauren Hu, A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy. Clinical neurosurgery. ,vol. 56, pp. 107- 118 ,(2009)
Istvan Boldogh, Sabine Grösch, Tapas K. Hazra, Thomas Grombacher, Sankar Mitra, Chilakamarti V. Ramana, Chilakamarti V. Ramana, Zhenping Chen, Bernd Kaina, Tapan Biswas, Regulation of Expression of the DNA Repair Gene O6-Methylguanine-DNA Methyltransferase via Protein Kinase C-mediated Signaling Cancer Research. ,vol. 58, pp. 3950- 3956 ,(1998)
Russell O. Pieper, Yuichi Hirose, Mitchel S. Berger, Abrogation of the Chk1-mediated G2 Checkpoint Pathway Potentiates Temozolomide-induced Toxicity in a p53-independent Manner in Human Glioblastoma Cells Cancer Research. ,vol. 61, pp. 5843- 5849 ,(2001)
Peter J. Houghton, Joanna S. Remack, Linda C. Harris, Thomas P. Brent, Wild-Type p53 Suppresses Transcription of the Human O6-Methylguanine-DNA Methyltransferase Gene Cancer Research. ,vol. 56, pp. 2029- 2032 ,(1996)
Russell O. Pieper, Yuichi Hirose, Mitchel S. Berger, p53 Effects Both the Duration of G2/M Arrest and the Fate of Temozolomide-treated Human Glioblastoma Cells Cancer Research. ,vol. 61, pp. 1957- 1963 ,(2001)
J-L Fischel, P Formento, G Milano, Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. British Journal of Cancer. ,vol. 92, pp. 1063- 1068 ,(2005) , 10.1038/SJ.BJC.6602428
Dai-Wu Seol, p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochemical and Biophysical Research Communications. ,vol. 416, pp. 222- 225 ,(2011) , 10.1016/J.BBRC.2011.11.053
Markus Christmann, Georg Nagel, Sigrid Horn, Ulrike Krahn, Dorothee Wiewrodt, Clemens Sommer, Bernd Kaina, MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. International Journal of Cancer. ,vol. 127, pp. 2106- 2118 ,(2010) , 10.1002/IJC.25229
J. Portnow, P. Frankel, S. Koehler, P. Twardowski, S. Shibata, C. Martel, R. Morgan, M. Cristea, W. Chow, D. Lim, V. Chung, K. Reckamp, L. Leong, T. W. Synold, A phase I study of bortezomib and temozolomide in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology. ,vol. 69, pp. 505- 514 ,(2012) , 10.1007/S00280-011-1721-X